Sanofi India Dividend 2024 announced at ₹117 per equity share. The ex-date of the dividend is 3 May 2024. Earlier, Sanofi India had given a dividend of ₹50 per equity share to its investors on March 7, 2024. The current price of Sanofi India Limited share is ₹8,757 as of April 4, 2024. Sanofi India’s 52-week high is ₹9,380 and its 52-week low is ₹5,400. Sanofi India has given returns of 50% in the last one year.
Sanofi India Limited Dividend History
Ex-Date | Dividend Amount | Dividend Type | Payment Date |
03 May, 2024 | ₹117 | Final | 13 June, 2024 |
07 March, 2024 | ₹50 | INTERIM | 20 March, 2024 |
28 April, 2023 | ₹194 | Annual | 10 June, 2023 |
28 April, 2023 | ₹183 | Bonus | 10 June, 2023 |
05 Aug, 2022 | ₹193 | Bonus | 22 Aug, 2022 |
12 April, 2022 | ₹181 | Annual | 04 May, 2024 |
12 April, 2022 | ₹309 | Bonus | 04 May, 2024 |
19 April, 2021 | ₹125 | Bonus | 27 May, 2021 |
19 April, 2021 | ₹240 | Annual | 27 May, 2021 |
29 June, 2020 | ₹106 | Annual | 06 Aug, 2020 |
29 June, 2020 | ₹243 | Bonus | 06 Aug, 2020 |
25 April, 2019 | ₹66 | Final | 06 June, 2019 |
Also Read: Yes Bank Share Price Target 2024, 2025, 2026, 2027, 2028
Sanofi India Limited Overview
Sanofi India was started in 1956. Sanofi India Limited is a big player in the Indian pharmaceutical industry. Sanofi India is a subsidiary of a multi-national pharmaceutical company Sanofi, headquartered in France. Sanofi India makes vaccinations and medication for diseases like Diabetes, Cardiovascular diseases, Oncology (Cancer), and Central Nervous System (CNS) disorders in India. Sanofi India has captured a significant market share in diseases like diabetes. Sanofi India has a good manufacturing and distribution network.
Sanofi India Limited Financials (2019-2022)
Particulars | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
Revenue | ₹3,164(Cr) | ₹2,991(Cr) | ₹3,031(Cr) | ₹2,841(Cr) |
Expenses | ₹2,505(Cr) | ₹2,272(Cr) | ₹2,262(Cr) | ₹2,109(Cr) |
EBITA | ₹700(Cr) | ₹761(Cr) | ₹1,326(Cr) | ₹907(Cr) |
Profit Before Tax | ₹599(Cr) | ₹677(Cr) | ₹1,257(Cr) | ₹864(Cr) |
Net Profit | ₹414(Cr) | ₹477(Cr) | ₹944(Cr) | ₹620(Cr) |
Sanofi India Limited Fundamentals
Particulars | Figures |
Market Cap | ₹19,909(Cr) |
P/E Ratio | 33.00 |
P/B Ratio | 19.60 |
Debt to Equity | 0.02 |
ROE | 59.40% |
Dividend Yield | 1.93% |
Book Value | 440.96 |
Face Value | 10 |
Also Read: TATA Power Share Price Target 2024, 2025, 2026
Sanofi India Limited Shareholding Pattern
Particulars | Shareholding pattern |
Promoters | 60.40% |
Mutual Funds | 11.51% |
Domestic Institutions (DII) | 10.96% |
Retail Investor | 10.82% |
Foreign Institutions (FII) | 6.31% |
Is Sanofi India Limited Good for Long-term Investment?
- Sanofi India has a good history of innovation and Sanofi India Limited has a good brand reputation in India. which increases brand trust.
- Sanofi India has a very diverse product portfolio due to which it can provide medicines for most of the diseases in India.
- Sanofi India is further expanding its R&D so that it can fulfill the medical needs of India.
- Due to the increasing population in India, demand for quality healthcare products is increasing in India which will benefit Sanofi India.
- Sanofi India can be a good option for investment of 5-10 years because that time is enough for the growth of a pharma stock. But we would recommend that you consult your financial advisor.
Conclusion
Sanofi India can be a good investment option. Sanofi India has shown considerable growth in the last few years. But we would advise you to analyze the stock thoroughly and consult your financial advisor. We do not give any kind of buy or sell advice. However, TrendFriend advises you to consult your experts for any investment.
Note: Do not invest based on the information given by this website. We are not SEBI registered. Our objective is to provide you with education and awareness about the stock market. Trendfriend.in and its authors are not liable for any losses. Always do your own research and consult your financial advisor before making any investment decision.